Astera Labs reported stronger-than-expected Q2 results and a raised price target to $310, yet shares fell 8% in trading.
Astera Labs (ALAB) posted second-quarter results that exceeded analyst estimates, driven by strength in its new Scorpio X product line. Despite the positive performance, shares declined approximately 8% on Wednesday.
Susquehanna lifted its price target on Astera Labs to $310 from $275, maintaining a bullish outlook. Analysts noted optimism around the Scorpio X lineup, though the stock’s reaction suggested investor caution.
The decline contrasts with the upward revision in price targets, highlighting a disconnect between analyst sentiment and market response.